Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epithelial ovarian cancer.

Martee L Hensley1

  • 1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Hensleym@mskcc.org

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Epithelial ovarian cancer, the deadliest gynecologic malignancy, often presents at advanced stages. Optimal surgical staging and debulking, followed by chemotherapy, are crucial for improving treatment and survival outcomes in these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uterine leiomyosarcoma progression: A study of serial recurrences.

Gynecologic oncology·2025
Same author

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Journal for immunotherapy of cancer·2025
Same author

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.

Gynecologic oncology·2025
Same author

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.

JCO precision oncology·2025
Same author

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2024

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Surgical Oncology

Background:

  • Epithelial ovarian cancer is the most lethal gynecologic malignancy, frequently diagnosed at advanced stages.
  • Effective management hinges on timely surgical intervention by gynecologic oncologists for accurate staging and tumor debulking.
  • Treatment strategies significantly impact patient survival rates.

Purpose of the Study:

  • To outline the current management paradigms for epithelial ovarian cancer.
  • To emphasize the critical role of surgical staging and cytoreductive surgery.
  • To discuss the role of chemotherapy and novel therapeutic approaches.

Main Methods:

  • Review of current treatment guidelines and surgical practices for epithelial ovarian cancer.
  • Analysis of the impact of surgical debulking and staging on patient outcomes.
  • Evaluation of chemotherapy regimens, including platinum-taxane-based treatments.
  • Consideration of interval cytoreductive surgery and the role of second-look procedures.
  • Discussion of management strategies for recurrent or relapsed disease and clinical trial participation.

Main Results:

  • Optimal surgical debulking and staging are paramount for improving treatment efficacy and survival in advanced epithelial ovarian cancer.
  • Platinum-taxane chemotherapy is the standard adjuvant treatment post-surgery for most patients.
  • Surgery alone may suffice for early-stage, low-risk tumors.
  • Interval cytoreductive surgery can benefit select patients with suboptimal initial debulking.
  • While recurrent disease is incurable, chemotherapy offers palliative benefits; novel approaches target minimal residual disease.

Conclusions:

  • Multidisciplinary management, integrating surgical expertise and chemotherapy, is essential for optimizing outcomes in epithelial ovarian cancer.
  • Accurate surgical staging and maximal tumor debulking remain cornerstones of initial treatment.
  • Ongoing research into novel therapies is crucial for improving long-term survival and managing relapsed disease.

Related Experiment Videos